Clinical Trial Update: CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of CCI-779 (temsirolimus) in locally advanced or metastatic pancreatic cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Pancreas
• Pancreatic Cancer

Drugs mentioned

• CCI-779 (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 2 | Status: COMPLETED